Stay updated on Influenza Vaccine Reactogenicity in Younger and Older Adults Clinical Trial
Sign up to get notified when there's something new on the Influenza Vaccine Reactogenicity in Younger and Older Adults Clinical Trial page.

Latest updates to the Influenza Vaccine Reactogenicity in Younger and Older Adults Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant changes, including the addition of new dose levels for the GSK4382276A vaccine and the removal of detailed study descriptions and criteria. The study's collaboration with CureVac remains, but the overall focus has shifted towards specific dose levels and their blinding methods.SummaryDifference25%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 7, 2025.SummaryDifference0.2%
- Check37 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous date of March 7, 2025, and version 2.14.2.SummaryDifference0.1%
- Check59 days agoChange DetectedThe webpage has updated its date references and location details, replacing previous dates and a specific location in Majadahonda with new dates and a location in Madrid.SummaryDifference0.9%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.9%
Stay in the know with updates to Influenza Vaccine Reactogenicity in Younger and Older Adults Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Influenza Vaccine Reactogenicity in Younger and Older Adults Clinical Trial page.